Center for Drug Evaluation and Research Director Janet Woodcock sounded an alarm about FDA's biosimilar program, warning it could "explode" from a potentially overwhelming workload and insufficient resources.
It suggests that user fees may not be enough to support the biosimilar program, which already has proven much more...